Bronchospasm medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 21: | Line 21: | ||
=== Muscarinic Acetylcholine Receptor Antagonist === | === Muscarinic Acetylcholine Receptor Antagonist === | ||
Since the neurotransmitter, [[acetylcholine]], is known to decrease sympathetic response by slowing the heart rate and constricting the [[smooth muscle tissue]]; ongoing research and successful clinical trials have shown that agents such as [[diphenhydramine]], [[atropine]] and [[Ipratropium bromide]] | Since the neurotransmitter, [[acetylcholine]], is known to decrease sympathetic response by slowing the heart rate and constricting the [[smooth muscle tissue]]; ongoing research and successful clinical trials have shown that agents such as [[diphenhydramine]], [[atropine]] and [[Ipratropium bromide]] are known to be effective for treating asthma and COPD-related symptoms. | ||
==References== | ==References== | ||
Revision as of 19:25, 19 February 2013
|
Bronchospasm Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Bronchospasm medical therapy On the Web |
|
American Roentgen Ray Society Images of Bronchospasm medical therapy |
|
Risk calculators and risk factors for Bronchospasm medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Medical Therapy
Beta 2 Agonists
Beta 2 adrenergic agonists are recommended for bronchospasm.
- Short acting (SABA)
- Long acting (LABA)
- Others
Muscarinic Acetylcholine Receptor Antagonist
Since the neurotransmitter, acetylcholine, is known to decrease sympathetic response by slowing the heart rate and constricting the smooth muscle tissue; ongoing research and successful clinical trials have shown that agents such as diphenhydramine, atropine and Ipratropium bromide are known to be effective for treating asthma and COPD-related symptoms.